Stock
CapsoVision is a commercial-stage medical technology company that develops advanced imaging and AI-enabled capsule endoscopy solutions. Its primary product is the CapsoCam Plus.
For the full year 2025, the company reported a total revenue of $13.6 million. The net loss per share, representing the Earnings Per Share (EPS), was $(1.03) for the same period.
CapsoVision held $10.1 million in cash and cash equivalents as of December 31, 2025. Furthermore, the company successfully completed its initial public offering in July 2025, generating $23.4 million in net proceeds.
What to Watch: The key question for CapsoVision is whether the 21.0% new account growth can translate into accelerating revenue as customer relationships mature, and whether the company can maintain its trajectory of narrowing losses without requiring additional capital raises that would dilute existing shareholders.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.
Source link
#CapsoVision #Financial #Performance #Review #Alphastreet
